Live Breaking News & Updates on Response Seen Regardless

Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor. ....

Xenofon Baraliakos , Eli Lilly , Bristol Myers Squibb , European Alliance Of Associations , Assessment In Spondyloarthritis International Society , European Union , Ruhr University Bochum Germany , International Congress On Spondyloarthritides , International Congress , Ruhr University Bochum , European Alliance , Spondyloarthritis International Society , Fabian Proft , Medical University , None Drug , Ankylosing Spondylitis Disease Activity Score , Bath Ankylosing Spondylitis Functional Index , Response Seen Regardless , Merck Sharp , Pain Management , Pain Management , Ankylosing Spondylitis Bechterews Disease , Ankylosing Spondylitis , Biologic Therapy , Social Issues , Fungal Infection ,